Hedge Fund - Ardsley Partners

Philip Hempleman Bio, Returns, AUM, Net Worth

Established in March 1987, Ardsley Partners operates as a hedge fund manager with its base located in Connecticut. Ardsley is a hedge fund specializing in long/short equity strategies, managing a portfolio with approximately $1 billion in assets. While the fund engages in global investments, it particularly favors companies associated with the chemical and chemical-related sectors.

Mr. Philip Hempleman, the Founder and Managing Partner of Ardsley Partners, assumes a pivotal role in overseeing all investment activities within the firm. With an extensive background, he previously held the position of Managing Director at the Trust Company of the West, where he effectively managed the Special Equity Strategy. Notably, from 1978 to 1982, Mr. Hempleman served as the portfolio manager for Oppenheimer Target and Special Strategies, achieving remarkable success as the Target Fund under his leadership emerged as the best-performing mutual fund in 1981 and 1982. Before joining Oppenheimer & Co., he contributed his expertise as an Assistant Treasurer at the Bankers Trust Company. In this capacity, Mr. Hempleman served as a Senior Analyst in the research department and as the portfolio manager for the Supplemental Equity Strategy. His educational credentials include an MBA from New York University and a BA from Indiana University.

Ardsley Advisory Partners manages discretionary assets totaling $789.3 million according to the Form ADV filed on June 2023. Their most recent 13F filing for Q3 2023 disclosed $447.8 million in managed 13F securities, showcasing a top 10 holdings concentration of 35.17%.

Philip Hempleman
Fund Profile
Filing Period:
Fund Name: Ardsley Partners
Manager Philip Hempleman
Portfolio Value $647,944,804
Change This QTR +1.45%
Fund Holdings Sector Distribution
Filing Period:
Last update:
No. Security Ticker Shares Value Activity % Port History
1. SPY 175,000 $83,179,250 NEW 12.83%
2. CLS 957,100 $28,023,888 +4% 4.32%
3. STKL 4,966,643 $27,167,537 -1% 4.19%
4. BIOX 1,727,573 $23,719,577 -7% 3.66%
5. HASI 781,750 $21,560,665 NEW 3.32%
News, Interviews and Investor Letters